Pulse Pharmaceuticals on Thursday announced that receipt of Drugs Controller General of India (DCGI) approval for its pioneering nanocarrier technology in Vitamin D3 delivery.South Asians & Diaspora
The company’s proprietary “Aqueol” platform technology is specifically designed to effectively deliver lipophilic compounds in water-based mediums. The nanotechnology is used to improve how well a drug works, its bioavailability, how easily it is tolerated, and the overall patient experience, said Pulse Pharma Managing Director KV Rambabu.
In a press release, the company claimed that clinical studies had demonstrated 50 to 60 percent higher serum vitamin D levels with Nano-carrier entrapped Vitamin D3 oral dispersion compared to conventional formulations.
